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Abstract
Background: To assess the clinical value of peritoneal washing cytology (PWC) in women with BRCA1 or BRCA2
mutations and women from a family with hereditary breast and/or ovarian cancer (HBOC) undergoing risk-reducing
salpingo-oophorectomy (RRSO) in detecting primary peritoneal cancer (PPC) or occult ovarian/fallopian tube cancer.
Methods: A retrospective study of patients with known BRCA1 or BRCA2 mutation or HBOC who underwent RRSO
at the Erasmus Medical Centre, Rotterdam, The Netherlands between January 2000–2014. Patients with an elevated
risk of malignancy prior to the procedure were excluded from primary analysis (elevated CA-125, an ovarian mass,
abdominal pain or another gynecological malignancy). A review of the literature was conducted.
Results: Of the 471 patients who underwent RRSO, a total of 267 cytology samples were available for analysis. Four
samples showed malignant cells, all four patients were diagnosed with ovarian and/or fallopian tube cancer at
histologic examination. A fifth patient, of whom no cytology sample was obtained during RRSO, developed primary
peritoneal cancer 80 months post RRSO.
Conclusions: This study failed to show that cytology is of value during RRSO in detecting primary peritoneal
cancer, however 36 % of patients with concomitant ovarian or fallopian tube cancer had positive cytology.
Therefore, the routine sampling of peritoneal washings during RRSO is not found to be useful to detect subsequent
PPC.
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Background
Peritoneal washing cytology (PWC) has been used for
years in gynecological surgery to detect metastasis and
to stage malignant gynecologic cancers. It has minimal
risk for the patient and may be useful in the detection of
early dissemination of cancer. Although PWC can be
done easily while performing laparoscopy, routine test-
ing in patients with presumed benign disease has been
discouraged to save money and to avoid distressing false
positive test results [1, 2]. In patients diagnosed with
cancer, such as ovarian, fallopian tube or endometrial
cancer, the PWC outcome gives additional information
about the prognosis [3] and has influence on postopera-
tive staging of ovarian and fallopian tube cancer [4,
5]. The main reason for performing PWC in patients
undergoing risk-reducing salpingo-oopherectomy
(RRSO), is to detect early ovarian and fallopian tube
cancer which may be too small to detect by histology
examination of tubes and ovaries, and to detect pri-
mary peritoneal carcinoma (PPC).
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The main indications for RRSO are risk-reducing sur-
gery in women at risk of developing ovarian or fallopian
tube cancer such as BRCA1 or BRCA2 germline muta-
tions or hereditary (breast) and ovarian cancer (HBOC)
[1]. Women affected by a BRCA1 or BRCA2 germline
mutation have a 20–40 % [6, 7] and 15–25 % [6] lifetime
risk, respectively, of developing a gynecologic cancer.
Percentages of finding unsuspected carcinomas at RRSO
vary from 6 to 17 % [8, 9] there is also a 5–6 % chance
of finding a serous tubal intraepithelial carcinoma
(STIC) at RRSO, which is thought to give rise to high
grade serous carcinoma [10]. RRSO is a highly protective
procedure against the development of ovarian- and fallo-
pian tube cancers in this patient group (hazard ratio of
RRSO for the development of breast and BRCA-related
gynecologic cancer: 0.21, 95 % CI 0.07–0.62) [11], how-
ever a 1–6 % lifetime risk of developing PPC still exists
after this procedure [12]. HBOC patients do not carry a
BRCA1 or BRCA2 mutation but have an increased risk
of developing breast and ovarian cancer [13].
PWC appears to be a harmless and effortless tech-
nique to detect malignant gynecologic cancers but it is
not completely clear yet how to interpret the findings. A
false positive PWC in women will cause unnecessary
anxiety and possibly leads to unnecessary diagnostic
testing. Conversely, a positive test result in women who
have (subclinical) PPC, PWC may lead to earlier diagno-
sis and possibly improve the prognosis. Studies on PPC
have shown that the median survival is 23.5 (95 % CI,
18.6–39.8) [14] to 42 (95 % CI 22–62) months [15], but
the advantage in survival for early diagnosis of PPC is
not known.
In this retrospective study of women with a known
BRCA mutation or a HBOC family undergoing RRSO,
first we investigated the clinical value of malignant PWC
in detecting ovarian and fallopian tube cancer and the
early detection of PPC. Second, we study the correlation
between PWC and tuba/ovarian malignancies and PPC
in the setting of RRSO.
Methods
This is a retrospective study of patients taken from data
in the electronic health records of the Department of
Gynecologic Oncology of the Erasmus MC Cancer Insti-
tute Rotterdam, The Netherlands. RRSO is performed in
patients with > 10 % risk of developing ovarian cancer.
Electronic health records were used to select patients
who underwent RRSO between January 2000 and Janu-
ary 2014. The criteria for HBOC were followed in ac-
cordance to our national guidelines [16]. To be certain
no patients were missed during the selection, the local
electronic pathology registry was searched, using the terms
‘ovary’ and ‘tube’ and all selected patients were cross-
checked in the FAMOND database (a database including
all patients with a high risk of developing ovarian and/or
breast cancer that have been treated in the Erasmus MC
Cancer Institute Rotterdam). Patients excluded from this
study include those whose salpingo-oophorectomy (SO)
was indicated because of pre-operative medical com-
plaints or suspicious abnormalities at transvaginal ultra-
sound (TVUS). Also patients undergoing SO because of
elevated CA-125 by follow-up were excluded. Because
CA-125 measurements were obtained routinely in patients
with a known BRCA mutation, patients with a retrospect-
ively elevated CA-125 post RRSO were not excluded. This
because the study aims to include all patients with an ab-
solute prophylactic indication for RRSO.
Since 2007, PWC has been routinely performed during
RRSO according to our hospital protocol. Surgery proce-
dures during RRSO included PWC, removing the ovar-
ies, fallopian tubes and mesosalpinx. Laparoscopy is the
standard procedure for performing a RRSO. As soon as
the peritoneal cavity is filled with CO2 and the instru-
ments are placed, then incidental free fluid is aspirated.
If free fluid is not present, 10-100 ml saline (0.9 %
natriumchloride solution) is introduced to lavage the
peritoneal cavity. Displacement of cervical, endometrial
and endosalpingeal tissues can occur and potentially dis-
lodge cells, thereby contaminating cytology fluids.
Therefore, PWC is performed immediately after opening
the peritoneal cavity, reducing the likelihood of dislodg-
ing cells [17]. The surgery report noted whether free
fluids or ascites was present in the peritoneal cavity and
if present, a PWC sample and/or (if available) ascites
was collected before manipulation of pelvic organs. In
our hospital, cytology and histology samples are sent to
two different laboratories, allowing for a double-blinded
study design. Pathologists do not consult each other,
except when results are inconclusive. The fluid was
centrifuged in the laboratory and stained using the Papa-
nicolaou and Giemsa method. Samples were categorized
according to the following categories, no analysis
possible because of poor quality of the sample, benign,
atypical, suspicious for malignancy or malignant cells.
The presence of psammoma bodies and endosalpingio-
sis was also noted, to prevent false positive malignant
findings [18]. Histology of the RRSO specimens was
assessed using microscopic examination, using the
standardized SEE-FIM protocol for the evaluation of
all specimens obtained from 2006 to present [19]. This
protocol maximizes the proportion of the fallopian
tube mucosa. An increase of approximately 60 %
surface area of the fimbria is obtained as compared to
the conventional serial cross-sectioning [19]. The find-
ings of the histology were classified in the following
categories: no malignancy, benign cyst, cystic teratoma,
adeno(fibro)ma, borderline tumor or malignancy of the
ovaries and/or fallopian tubes.
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Permission for this retrospective study was granted by
the medical ethical committee of our hospital, according
to the regulations (Medical ethical committee number:
MEC-2015-036) [20].
Data were collected and analyzed using SPSS version
21. The results were described using descriptive statis-
tical methods (mean ± SD). Results were analyzed using
the Student T test for continuous data and the Chi
square test or Fischer’s exact test for binary data, de-
pending on sample size of the subgroup. A p-value <0.05
was considered to be significant. Calculation of sensitiv-
ity, specificity, number-needed-to-treat (NNT), positive
and negative predictive value (PPV and NPV) and the
positive and negative likelihood ratio (LR) were planned.
Furthermore, the risk factors of developing PPC were
planned to be analyzed using logistic regression. A
Kaplan Meier survival plot was planned for patients with
positive and negative PWC. The difference between the
sensitivity and specificity of ascites versus PWC samples
was also planned to be calculated, along with the differ-
ence in malignant outcome of histologic examination of
the RRSO specimen.
This study also conducted a literature search using
PubMed. The relevant articles are discussed in the dis-
cussion section of this article.
Results
Five hundred and ten patients were included during the
study period. 39 patients were excluded due to indica-
tions for (RR)SO which were not prophylactic (see
Fig. 1). Seven of the included patients already underwent
an ovariectomy between 1995 and 1998, but received an
additional salpingectomy between January 2000 and
January 2014. Of the remaining 471 patients, 288 had
BRCA1 mutations, of those one patient had a 50 %
chance of having a BRCA1 mutation, 126 had BRCA2
mutations, 2 had both BRCA1 and BRCA2 mutations.
Of the 55 patients in the HBOC group, 12 did not meet
all the criteria for HBOC and in four patients informa-
tion about family history was not available. The median
age of patients at the time of RRSO was 48 years (range,
33–78 years). See Table 1 for descriptive statistics for
this group.
In one patient both ovaries remained in situ because
of multiple adhesions discovered during the RRSO pro-
cedure. Cytology samples were not available for this pa-
tient. PWC was available for 280 patients. The presence
or absence of ascites was reported in 21 surgical reports,
13 ascites samples were available for analysis. PWC sam-
ples were obtained in 48 patients (24.6 %) of the RRSO
procedures between January 2000 to December 2006
Fig. 1 Flowchart of excluded patients and cytology samples
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and from January 2007 to December 2013 in 232 pa-
tients (84.1 %). Further analysis did not show a signifi-
cant difference in the number of malignant PWC
samples between these periods (p = 0.51). The quality of
23 PWC samples were too poor for analysis and the re-
port of one PWC sample was missing in the electronic
patient file. Malignant cells were detected in four of the
remaining 256 PWC samples. No atypical or malignant
cells were found in the ascites samples. Since some of
the samples were inadequate, PWC and ascites samples
Table 1 Descriptive statistics of the total group of patients who
underwent RRSO (n = 471)
Number Percentage Range




-BRCA1 and BRCA2 2 0.4
-HBOC 55 11.7
CA-125 preoperative (n) 466
-median (U/ml) 14.0 4.0–93.0
-elevated CA125 (>35 U/ml) (n) 10 2.1
















-iatrogenic injury (intestine/ureter) 3
-incomplete removal of the ovaries 1




Menopausal status (n) 447
-postmenopausal 187 41.8
-because of hormonal breast
cancer treatment
32 17.1
-because of previous ovariectomy 8 4.3
-premenopausal 241 53.9
-perimenopausal 19 4.3
-because of hormonal breast
cancer treatment
10 52.6
HRT in premenopausal women (n) 217
-postoperative usage of HRT 97 45.3
Follow up (median, mo) (n = 375) 55.8 0.6–169.0
-deceased in FU 19 5.1
-age (median, year) 55.5 43.1–72.0
-development of breast cancer in FU 57 12.1
-development of PPC in FU 1 0.2
-development of other malignancy 22 4.7
Table 1 Descriptive statistics of the total group of patients who
underwent RRSO (n = 471) (Continued)
Previous breast cancer (n) 195 41.4




PWC sample not available 191 40.6
PWC sample available 280 59.4
-PWC analyzable 257 91.8
-PWC malignant 4 1.6
-PWC atypical 1 0.4
Ascites sample reported 21 4.5
-Ascites sample available for analysis 13 61.9
-ascites malignant 0 0




-primary serous adenocarcinoma 4 0.9
-granulosa cell tumor 1 0.2
-borderline tumor 1 0.2
-stromal hyperplasia 2 0.4






Fallopian tube (n) 470
-benign 433 92.1
-adenocarcinoma 5 0.6
-serous large cell carcinoma 1 0.2
-benign mesothelial hyperplasia 1 0.2
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were analyzed as one group, resulting in a total of 267
samples. In two patients both ascites and PWC samples
were reported in the surgical report. Because all of these
samples were benign, PWC and ascites samples were
considered as one sample for each patient (see Fig. 1).
Malignancy in cytology samples was significantly related
to malignancy in histology samples in the ovaries and
fallopian tubes (p < 0.001). The results of these findings
are represented in Table 2. In total 11 patients had fallo-
pian tube or ovarian cancer, all primarily diagnosed with
the RRSO specimen. In 4 (36 %) of these 11 patients the
PWC samples were positive.
Surgery reports were checked for uterine manipulator
factors prior to the collection of cytology samples which
could have caused potential dislodgement of cells, result-
ing in contamination of the samples. In surgery reports
of four patients with malignant PWC, only one men-
tioned the timing of PWC sampling. The sampling had
taken place after insufflating the abdominal cavity and
inspection of the abdominal cavity, uterus and fallopian
tubes. In one of the patients in which the timing of
PWC was not mentioned, the laparoscopic procedure
was converted to open surgery because of adhesions.
Of the four patients with malignant PWC, two patients
had fallopian tube cancer (FIGO stage IIC and IIIA) and
two ovarian cancer (FIGO stage IIC and IIIC). All hist-
ology samples were conclusive and none of the malig-
nancies was detected through the malignant PWC
sample. After a median FU of 58 months (range, 46–
111) no evidence of disease was found in three of the
four patients. The fourth patient, with progressive ovar-
ian carcinoma, was lost in follow up.
One sample in this study was reported as atypical
PWC and although malignant cells were reported in the
first cytology report, no adenocarcinoma was revealed in
the RRSO specimen. Both the RRSO specimen and the
PWC sample were reassessed. Pathologists concluded
there was no malignancy in the RRSO specimen and
they attributed the atypical cells in the PWC to endo-
metriosis. This conclusion was confirmed by reference
pathologists at the request of second opinion. This pa-
tient was followed up for 39 months without having de-
veloped malignancy and then was lost to FU after that.
Only one patient, aged 60 years did develop PPC
80 months post RRSO, although no malignancy was
found at RRSO even though no PWC or ascites samples
were collected. The diagnosis of PPC was confirmed by
biopsies and the patient was treated with induction
chemotherapy, interval debulking surgery and adjuvant
chemotherapy. To date, no progression or recurrence
has been noted during the 34 months FU at our hospital.
In seven other cases ovarian or fallopian tube malig-
nancy was revealed by histology, but cytology samples
did not show malignant cells. The histology of the ovar-
ian and tubal cancers are depicted in Table 1.
Discussion
Four malignant cytology samples were found in this 14-
year retrospective study of women who underwent
RRSO, which included cytology samples of 471 women
with BRCA1 and/or BRCA2 mutation or a strongly posi-
tive family history (HBOC). Two of these patients had
ovarian cancer and two patients had fallopian tube can-
cer with metastases in the ovaries at histologic examin-
ation. In follow-up, no PPC developed in patients who
underwent PWC sampling. Only one patient (without
PWC obtained at the time of the RRSO) developed PPC
at 80 months follow-up, which was confirmed by biopsy.
In seven other patients a malignancy was found at hist-
ology, but PWC did not reveal any malignant cells.
There were significantly more malignant cytology sam-
ples in the group of patients in whom the RRSO speci-
men revealed malignancy at histopathologic examination
(p < 0.001). Because histologic and cytological examina-
tions are analysed in independant laboratories, it is cer-
tain that no malignant outcomes at histology were found
because of malignant outcomes at cytology. One PWC
sample showed atypical cells. Studies have shown that
reactive mesothelial cells, endometriosis and endosalpin-
giosis could give false positive results [18]. Dislodgement
of cells could contaminate samples. Of four patients with
malignant PWC, only one surgery report mentioned the
timing of PWC sampling, which occurred immediately
following the inspection of the abdominal cavity, uterus
and fallopian tubes. Another surgery report of a patient
with malignant PWC did not mention the timing of
PWC, but noted that the procedure was converted be-
cause of adhesions. Difficulties introducing instruments
and CO2 insufflation prior to conversion could have
caused contamination of the sample.
Literature shows that while PWC is able to detect ma-
lignant cells in patients undergoing RRSO [1, 17, 21–
24], but the numbers of positive PWC samples in these
studies are minimal and the added value of performing a
PWC in detecting PPC remains uncertain. These studies
are depicted in Table 3. PWC was performed in 836 pa-
tients and malignancy was demonstrated in 15 (1.8 %) of
those patients, 14 (93 %) were found to have concomi-
tant ovarian/fallopian tube cancer. Two of these 14 pa-
tients (13.0 %) had concomitant ovarian/fallopian tube
Table 2 Results of peritoneal washing cytology in RRSO (n = 267)
Malignant cytology Benign cytology Total
Malignant histopathology 4 7 11
Benign histopathology 0 256 256
Total 4 263 267
P < 0.001, using the Fisher’s exact test
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Colgan et al. [12] 35 NA NA 35 3a 2a 1 0 0 1a NA NA
Leunen et al. [14] 51 45g 25 28 0 - 0 - - - - -
Eitan et al. [13]b 130 48 (33–78) 20 117 0 - 0 - - - - -
Haldar et al. [1] 113 52 (35–78) 34 110 2 2c 0 0c 0c 0 NA NA
Landon et al. [15] 116d NA NA 116d 0d 0d 9 0 - - NA NA
Chen et al. [11] 163 NA NA 163 6 6 6 0 0e 0 NA NA
Present study Blok et al. 471 48 56 267 4 4 7 0 0f 0 47.6 (SD, 8.5) 58
Total 1079 836 15 14 23 0 0 1
Abbreviation: NA not available, SD standard deviation
a) In one of three patients with a malignant PWC, histopathology did not show any malignancy. No malignancy was detected at second-look laparotomy in peritoneal biopsies and PWC. The patient was treated with
chemotherapy and there is no evidence of disease 10 months FU. b) This study also included patients for whom RRSO was indicated because of a personal history of breast cancer. c) The authors report that in total
two women had a positive PWC, histological evidence of ovarian and/or fallopian tube cancer and histological evidence of PPC at time of RRSO. The authors of this article interpret these results as ovarian and/or fallopian tube
cancer with peritoneal metastasis. d) One patient had a malignant PWC, but no malignancy at histopathology (confirmed by four cytopathologists). The patient was treated with chemotherapy for presumed PPC. At second-
look laparotomy, peritoneal biopsies and PWC did not reveal any malignancy. The patient had no evidence of disease 118 months FU. Because of the doubtful diagnosis of PPC, this sample was not taken into account in this
article. e) One patient with malignant PWC and histopathological evidence of ovarian and/or fallopian tube cancer, developed PPC at 47 months FU. Because of the previous ovarian and/or fallopian tube cancer in this patient,
we would prefer to call this finding recurrence of disease instead of PPC. Another patient with benign PWC developed PPC or recurrence of ovarian carcinoma at 81 months FU. f) In this study, one patient developed PPC












cancer with peritoneal metastases. There were no pa-
tients diagnosed with subsequent PPC. Ovarian and/or
fallopian tube cancer were found in 37 patients, of
whom 14 patients (37.8 %) had a positive PWC sample.
In one patient (0.12 %) with a malignant PWC histologic
examination of the RRSO specimen did not reveal any
malignancy [22]. In total, 569 PWC samples were col-
lected. Eleven of these samples were positive for malig-
nancy and one of these PWC samples was false positive
when looking at ovarian and fallopian tube cancer (see
Table 3). In most studies, the SEE-FIM protocol- that
examines the fimbriated end more extensively- was not
used. This could have caused false negative findings dur-
ing histological examination of the RRSO specimen. This
could provide an explanation for the patient in the study
of Colgan et al. [22] with a malignant PWC, but no ma-
lignancy in the RRSO specimen. Additional information
provided by Leunen et al. [23] none of the patients de-
veloped PPC to date. Unfortunately, the rest of the au-
thors of the studies listed in Table 3 were not willing or
able to provide more information about the recent FU of
their patients. It is possible that due to publication bias
studies with high incidence of malignant PWC are
published.
Since 2007 the RRSO protocol in our hospital states
that PWC should be collected routinely. In our study,
we notice that PWC was collected more frequently in
the last seven years of the study period then when com-
pared with the first seven years. This may also indicate
that in the first half of the study period the indication
for obtaining PWC was different from the second half,
but no difference in the amount of malignant PWC sam-
ples was found between the two 7-year periods (p =
0.51). This study included all patients who underwent
RRSO up to January 2014, which caused a shorter follow
up time for patients who were included more recently.
Though the overall median FU period is relatively long
(median, 55.8 months (range, 0.6–169.0)). This study ex-
cluded all patients who underwent RRSO because of sus-
pected malignancy. A further, more extended statistical
analysis was not possible with the low incidence of PPC.
This study, which included the largest number of cy-
tology samples of patients undergoing RRSO to date,
failed to show that cytology is of value during RRSO for
early detection of PPC. Malignant cytology samples were
extremely rare (1.5 %) and if present, malignancy was
found in the ovaries and/or fallopian tubes. In literature
only two patients (out of 569 PWC samples) with malig-
nant PWC who had ovarian/fallopian tube cancer with
peritoneal metastasis were reported. Including our study,
two of 836 (0.24 %) patients with positive PWC devel-
oped concomitant PPC. No patients developed subse-
quent PPC. Furthermore, malignant PWC samples failed
to add any value to histopathological examination in
detecting ovarian and/or fallopian tube cancer when
using the SEE-FIM protocol.
Although the collection of cytology samples is rela-
tively simple, it is costly. Our pathology department
charges an amount of €77.09 (USD 83.53) per cytology
sample, which includes all technical costs and patholo-
gists honorary.
Conclusions
We recommend that PWC should not be practiced rou-
tinely at RRSO in high risk patients, preventing unneces-
sary testing and use of resources. In case of malignancy at
histopathology we suggest to perform PWC at second-
look staging surgery.
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